



The Extent of B-cell Activation and Dysfunction Preceding Lymphoma Development

L. Shepherd¹, ÁH Borges², R Harvey³, M Bower⁴, A Grulich⁵, M Silverberg⁶, J Weber⁷, M Ristola⁸, J-P Viard⁹, J Bogner¹⁰, P Gargalianos-Kakolyris¹¹, C Mussini¹², K Mansinho¹³, I Yust¹⁴, D Paduta¹⁵, D Jilich¹⁶, T Smiatacz¹⁷, R Radoi¹⁸, J Tomazic¹⁹, P Plomgaard²¹, R Frikke-Schmidt²¹, J Lundgren², A Mocroft¹ on behalf of EuroSIDA in collaboration with The Binding Site

¹Research Department of Infection and Population Health, University College London, London, UK. ²CHIP, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark. ³Charing Cross Oncology Laboratory and Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College Healthcare National Health Service Trust, London, UK. ⁴National Centre for HIV Malignancy, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. ⁵Kirby Institute, The University of New South Wales, Sydney, NSW, Australia. ⁶Kaiser Permanente Northern California, Oakland, CA, USA. ⁷Imperial College London, London, United Kingdom. ⁸Division of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁹AP-HP, Centre de Diagnostic et de Thérapeutique, Hôpital de l'Hôtel-Dieu, Paris, France. ¹⁰Department of Internal Medicine IV, University of Munich, Munich, Germany. ¹¹First Department of Internal Medicine and Infectious Diseases Unit, General Hospital of Athens "G. Gennimatas," Athens, Greece. ¹²Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Azienda Policlinico, Modena, Italy. ¹³Department of Infectious Diseases, Hospital Egas Moniz – Centro Hospitalar Lisboa Ocidental (CHLO), E.P.E., Lisboa, Portugal. ¹⁴Ichilov Hospital, Israel. ¹⁵GOCGEOZ (Gomel Regional Centre for Hygiene), Gomel, Belarus. ¹⁶Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University, Prague, Czech Republic. ¹⁷Infectious Diseases Department, Medical University of Gdańsk, Smoluchowskiego, 18 PL-80-214 Gdańsk, Poland. ¹⁸Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babeş", Bucharest, Romania. ¹⁹Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia. ²⁰Department of Clinical Biochemistry Rigshospitalet, Copenhagen, Denmark

BACKGROUND

- Despite effective treatment, NHL and HL incidence in HIV+ people remains around 10 and 11 fold higher than in the HIV- population respectively.
- B-cell dysfunction and/or activation is thought to contribute to lymphoma development in HIV+ people, however the mechanisms driving pathogenesis of lymphomas in the HIV+ setting is poorly understood.

AIM

To describe the kinetics and predictive value of markers of B-cell dysfunction prior to lymphoma diagnosis.

METHODS

Design

A nested-case-control study of 73 HIV+ people with lymphoma (52 non-Hodgkin lymphoma and 21 Hodgkin lymphoma) and 142 lymphoma free HIV+ matched-controls were selected from the EuroSIDA cohort. Cases and controls were matched on date of first and last sample preceding lymphoma diagnosis (or equivalent date in controls), age and CD4 cell count at first sample, gender and region of Europe. Incidence-density sampling of controls was used to select controls.

Measurements

Prospectively stored plasma samples before lymphoma (or matched date in controls) were measured for markers of B-cell dysfunction and activation:

- Free light chain[FLC]-κ, and FLC-λ.
- Immunoglobulin [Ig]G and IgM.

Kits for measurements were provided by **The Binding Site**.

Statistical methods

- Mixed models were used to describe kinetics in the time before diagnosis (or equivalent date in controls).
- Conditional logistic regression investigated associations between markers and lymphoma <2 and >2 years prior to diagnosis.

RESULTS

Baseline

- 215 men were included, with a median of 2.0 (interquartile range [IQR]: 0.4–4.3) years between first and last sample, and 9 (IQR 4 - 32) months between last sample and lymphoma in cases.
- Baseline characteristics for cases and controls are shown in table 1. Cases differed from controls according to current HIV-Viral load (HIV-VL) and Cart use. Cases and controls were well matched on other demographic variables.

Trajectories

- The trajectories of immunoglobulins and free light chains prior to lymphoma diagnosis is shown in **figure 1**. After adjustment, the largest difference was observed for IgM, in which cases were declining by 7% (95%CI: -10, -3) per year, but levels were stable in controls (%Change per year: 0 95%CI-3, 3%, P for difference<0.01). Levels of IgG were also declining in cases, but stable in controls (P for difference was 0.10).

Factors associated with marker levels

- Associations between demographic and HIV-related factors and marker levels in the control population are shown in **figure 2**.
- Higher FLC-κ, FLC-λ, and IgG were all associated with lower current CD4 and higher FLC-κ and IgG and levels were also associated with not being on treatment.
- IgM was associated with higher HIV-VL and not being on cART, and borderline associated with higher Nadir CD4 and lower current CD4.

Odds of developing a lymphoma during prospective follow-up

- The odds of lymphoma development for a 2 fold-higher marker level ≤2 and > 2 years before lymphomas are shown in **Figure 3**.
- Associations were not evident ≤ 2 years prior to diagnosis, except for FLC- λ where the association was borderline significant.
- Proportionately high levels of both FLC-κ and FLC-λ (a marker of polyclonal expansion¹) was associated with lymphoma >2 years prior to diagnosis (OR: 4.74 95%CI: 1.71 – 27.56), but not ≤ 2 years prior (1.62 94%CI: 0.54, 5.05). Having a disproportionately high level of one FLC (a marker of monoclonal expansion¹) was not associated at either time point.
- Of the HIV related markers – HIV-VL AUC was associated with higher risk in sample ≤ 2 years prior to diagnosis, however, HIV-VL was predictive in the long term (**Figure 4**).


CONCLUSIONS

- FLC-lambda, FLC-kappa and IgG were higher >2 years before lymphoma diagnosis, but the difference diminished nearer diagnosis, which is in keeping with other studies.
- B-cell dysfunction, as demonstrated by polyclonal hyperglobulinemia, occurred many years prior to lymphoma development.
- The association between FLC- κ, FLC- λ, and IgG and lymphomas was weak and unlikely to be a strong candidate for identifying those at highest risk of developing lymphomas.


¹Monoclonal elevations: FLC-kappa >19.4 mg/L or FLC-lambda > 26.3 mg/L and FLC-K/L not between 0.26 – 1.65. Polyclonal elevations: FLC-kappa >19.4 mg/L or FLC-lambda > 26.3 mg/L and FLC-K/L between 0.26 mg/L – 1.65 mg/L. Normal levels: FLC-κ <19.4 mg/L and FLC-λ <26.3 mg/L. A ratio of FLC-κ to FLC-λ (FLC- κ/λ) outside of the range of 0.26 – 1.65 is considered abnormal

Factors	Total	Lymphoma diagnosis		P
		Cases	Controls	
	N (%)			
Total	216 (100)	73 (100)	143 (100)	-
Male gender ²	193 (89.4)	65 (89.0)	128 (89.5)	-
Risk group				
Homosexual	114 (52.8)	41 (56.2)	73 (51.0)	0.39
Other	102 (47.2)	32 (43.8)	70 (49.0)	
Non-white Ethnicity	180 (83.3)	56 (76.7)	124 (86.7)	0.06
On cART ²	158 (73.1)	46 (63.0)	112 (78.3)	0.02
	Median (IQR)			
Age (years) ³	42 (37.50)	43 (37.51)	42 (37.49)	0.47
CD4 count (cells/mm ³) ²	318 (208,477)	316 (180,500)	319 (213,461)	0.06
Log ₁₀ HIV VL (copies/ml)	2.3 (1.7,3.3)	2.8 (1.9,4.0)	2.1 (1.6,2.9)	<0.1
Log ₁₀ AUC of HIV VL (copy years/ml)	4.3 (3.6,5.0)	4.5 (3.6,5.1)	4.2 (3.6,5.0)	0.51
FLC-κ (mg/L)	21.8 (14.5,31.4)	27.7 (19.2,45.0)	18.6 (13.7,27.2)	<0.1
FLC-λ (mg/L)	32.0 (23.4,50.5)	39.9 (28.1,62.1)	29.4 (20.8,41.0)	<0.1
IgG (g/L)	14.3 (11.1,17.8)	15.8 (12.5,19.6)	13.2 (10.3,16.9)	<0.1
IgM (g/L)	0.8 (0.5,1.3)	1.1 (0.7,1.7)	0.8 (0.5,1.1)	0.02

¹Date of first plasma sample was considered baseline. ²Matched variable. ³ART defined as ≥2 antiretroviral drugs



¹Percent changes were adjusted for Age and CD4 at earliest sample, center region and gender, *P (slope) <0.05



¹Adjusted for region, race





Figure 4: Odds ratio of lymphoma associated with a 10-fold increase in HIV markers, ≤2 and > 2 years prior to diagnosis



The EuroSIDA Study Group
 The multi-centre study group, EuroSIDA (national coordinators in parentheses):
 Argentina: B. Linares, Hospital de Infecciones, Buenos Aires; Australia: B. Smeeth, Monash Medical Centre, Melbourne; Austria: D. Fuchs, Medical University of Vienna; Belgium: J. De Weert, Ghent University Hospital; Brazil: M. S. de Oliveira, Hospital de Infeções, Universidade Federal de Minas Gerais; Canada: J. S. Ross, St. Michael's Hospital, Toronto; Chile: M. A. Valenzuela, Hospital de Infecciones, Universidad de Chile; China: J. Wang, Beijing Youan Hospital; Colombia: J. A. Rodríguez, Hospital de Infecciones, Universidad de Bogotá; Denmark: J. H. Christensen, Rigshospitalet, Copenhagen; France: J. P. Viard, Hôpital de l'Hôtel-Dieu, Paris; Germany: M. Müller, Charité - Universitätsmedizin Berlin; Greece: G. G. Panagoulas, University of Athens; Hong Kong: J. H. Ip, Prince of Wales Hospital; India: S. K. Ghosh, All India Institute of Medical Sciences; Iceland: S. Thorgeirsdóttir, Landspítali, Reykjavík; Ireland: J. O'Keefe, St. James's Hospital, Dublin; Israel: I. Yust, Ichilov Hospital, Beer Sheva; Italy: M. Ristola, Azienda Ospedaliera di Padova; Japan: T. Saito, National Center for Global Health and Medicine; Korea: J. H. Park, Seoul National University Hospital; Latvia: J. K. Strupelis, Rigshospitalet, Riga; Lithuania: J. V. Kasiulis, Lithuanian University of Health Sciences; Luxembourg: J. M. Ristola, Centre Hospitalier de Luxembourg; Malaysia: M. S. Ismail, Hospital Kuala Lumpur; Mexico: J. A. Garcia, Hospital General de México; Netherlands: J. M. A. Schouten, Radboud University Medical Centre; New Zealand: J. A. Hensley, Auckland City Hospital; Norway: J. H. Christensen, Oslo University Hospital; Pakistan: M. A. Khan, Aga Khan Hospital, Karachi; Peru: J. A. Garcia, Hospital General de Lima; Poland: J. M. Ristola, Medical University of Lodz; Portugal: A. H. Borges, Hospital Egas Moniz; Romania: R. Radoi, Victor Babeş Hospital, Bucharest; Russia: A. V. Kozlov, Federal Scientific Center of Information Medicine and Biotechnology; Serbia: M. Stankovic, University of Belgrade; Singapore: J. H. Ip, Prince of Wales Hospital; South Africa: J. H. Ip, Prince of Wales Hospital; Spain: J. M. Ristola, Hospital General de Madrid; Sweden: J. H. Christensen, Rigshospitalet, Stockholm; Switzerland: J. M. Ristola, University of Zurich; Taiwan: J. H. Ip, National Taiwan University Hospital; Thailand: J. H. Ip, Prince of Wales Hospital; Turkey: J. H. Ip, Prince of Wales Hospital; Ukraine: J. H. Ip, Prince of Wales Hospital; United Kingdom: J. H. Ip, Prince of Wales Hospital; United States: J. H. Ip, Prince of Wales Hospital; Venezuela: J. H. Ip, Prince of Wales Hospital.

The EuroSIDA Study Group is provided by the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement 601691. The EuroSIDA Study Group is also supported by the National Institute for Health Research (NIHR) under grant reference number 120156. The EuroSIDA Study Group is also supported by the Swiss National Science Foundation (Grant 108717). Study supported by grant 120156 from the Danish National Research Foundation.

